Charles (Charlie) Fuchs, M.D., M.P.H.

Charlie is a Senior Advisor on the Frazier Life Sciences team.

Charlie joined the Frazier Life Sciences team in 2025, bringing extensive expertise as an innovator and executive leader. Throughout his career, he has demonstrated a remarkable ability to advance clinical, research, and biopharma organizations. Most recently, Charlie served as Senior Vice President and Global Head of Product Development for Oncology and Hematology at Roche. In this role, he led the development and execution of a new, comprehensive global strategy for Roche’s Oncology and Hematology division — driving ambitious targets for substantial portfolio growth, the approval of multiple new therapies and indications across cancer and blood disorders, and the strategic acquisition of notable external assets to strengthen the division’s portfolio.

Prior to his work with Genentech and Roche, Charlie was the leader of the Yale Cancer Center and Smilow Cancer Hospital. He managed a highly integrated, state-of-the-art clinical and research operation spanning 16 facilities across New England. During his tenure, he played a key role in launching several biotech start-ups rooted in Yale science. In addition, Charlie served on advisory boards for numerous cancer centers, foundations, biotechnology, and pharmaceutical companies, and co-founded Evolveimmune Therapeutics.

Charlie previously held the position of Professor of Medicine at Harvard Medical School and served as Chief of the Gastrointestinal Oncology Division at Dana-Farber Cancer Institute and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer.

Charlie received his M.D. and M.P.H. from Harvard University and holds a B.A. in Biochemistry from the University of Pennsylvania. He completed post-graduate training in Internal Medicine, Medical Oncology, and Hematology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. Charlie has authored more than 700 scientific publications and co-authored the book, A New Deal for Cancer: Lessons from a 50 Year War.